Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a open-label study in patients with metastatic breast cancer to evaluate the
antitumor activity and safety of weekly dose-dense paclitaxel liposome injection compared to
3-weekly regimen.